Sernova Biotherapeutics Inc (TSX:SVA)

Sernova Biotherapeutics Income Statement

Financials in millions CAD. Fiscal year is November - October.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Apr 30, 2025	Oct 31, 2024	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021	Oct 31, 2020
Selling, General & Admin	8.27	8.97	8.46	7.86	2.3	2.5
Research & Development	12.69	22.69	32.04	16.9	4.64	2.76
Operating Expenses	20.96	31.66	40.5	24.75	6.94	5.26
Operating Income	-20.96	-31.66	-40.5	-24.75	-6.94	-5.26
Interest Expense	-1.03	-0.59	-0.03	-0.05	-0.01	-0.01
Interest & Investment Income	0.13	0.39	1.5	0.58	0.07	0.04
Currency Exchange Gain (Loss)	-0.07	-0.34	0.04	-0.13	-0.04	-0.01
Other Non Operating Income (Expenses)	-	-	-	-0.07	-0.05	-0.08
EBT Excluding Unusual Items	-21.93	-32.2	-39	-24.42	-6.97	-5.32
Gain (Loss) on Sale of Assets	-	0.02	-	-	-	-
Pretax Income	-21.93	-32.19	-39	-24.42	-6.97	-5.32
Income Tax Expense	0.05	0.01	-	-	-	-
Net Income	-21.98	-32.19	-39	-24.42	-6.97	-5.32
Net Income to Common	-21.98	-32.19	-39	-24.42	-6.97	-5.32
Shares Outstanding (Basic)	319	307	303	274	246	197
Shares Outstanding (Diluted)	319	307	303	274	246	197
Shares Change (YoY)	5.24%	1.19%	10.87%	11.43%	24.45%	12.17%
EPS (Basic)	-0.07	-0.10	-0.13	-0.09	-0.03	-0.03
EPS (Diluted)	-0.07	-0.10	-0.13	-0.09	-0.03	-0.03
Free Cash Flow	-16.07	-18.9	-30.44	-14.75	-6.86	-3.94
Free Cash Flow Per Share	-0.05	-0.06	-0.10	-0.05	-0.03	-0.02
EBITDA	-20.67	-31.25	-40.19	-24.45	-6.69	-5.12
D&A For EBITDA	0.3	0.41	0.31	0.3	0.24	0.14
EBIT	-20.96	-31.66	-40.5	-24.75	-6.94	-5.26

Updated Mar 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.